

# VANQUISH-1 STUDY DESIGN: PHASE 3 TRIAL OF SUBCUTANEOUS VK2735 IN ADULTS WITH OVERWEIGHT OR OBESITY

Karen Modesto, MD; Summer Ji, MS; Scott Stubbe; Tavette Neskorik; Brian Lian, PhD  
Viking Therapeutics, Inc, San Diego, CA, USA

ObesityWeek 2025 • 4–7 Nov 2025  
Atlanta, Georgia


## INTRODUCTION

- Nearly 75% of US adults have overweight or obesity, with approximately 42% having obesity<sup>1,2</sup>
- Excess body weight represents one of the most prevalent and fastest growing chronic health conditions in the United States and worldwide<sup>3</sup>
- Obesity is associated with increased mortality and risk of type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, stroke, sleep apnea, some cancers, and arthritis, as well as psychosocial difficulties<sup>4</sup>
- Studies have shown that reduction of excess body weight can reduce morbidity and mortality, which is correlated with the magnitude of weight loss<sup>5</sup>
- VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
- In the Phase 2 VENTURE study (NCT06068946), VK2735 significantly reduced body weight in patients with obesity/overweight at 13 weeks  
> See Bays poster in Thursday 11/6/2025 session, 2:30 pm–3:30 pm

## VANQUISH-1 WILL ASSESS THE EFFICACY AND SAFETY OF VK2735 IN A LARGE, DIVERSE, PATIENT POPULATION

### Study Design

- VANQUISH-1 (NCT07104500) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel arm study
- The duration of the study is 78 weeks, with a 6-week follow-up period
- Approximately 4,500 participants will be randomized in the study
- Participants with obesity or overweight will be randomized 3:2:3:3 to the study arms below and will be stratified by sex
  - Matched placebo
  - 7.5 mg weekly SC VK2735
  - 12.5 mg weekly SC VK2735
  - 17.5 mg weekly SC VK2735



### Objectives

- VANQUISH-1 will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735

### Key Study Endpoints at 78 weeks

- Primary Endpoint**: Percentage change in body weight from baseline
- Key Secondary Endpoints**:
  - ≥5% body weight reduction
  - ≥10% body weight reduction
  - ≥15% body weight reduction
  - ≥20% body weight reduction
- Additional Outcomes**:
  - Functional Mobility**: Physical functioning (SF-36 v2, IWQoL)
  - Cardiovascular & Metabolic Health**: hsCRP, MACE, ALT, AST, eGFR
  - Mental Health**: SF-36 v2, IWQoL
  - Work Productivity**: Work Productivity & Activity Impairment


## DIVERSITY PLAN

- Developed to promote broad, inclusive participation to improve the relevance of trial outcomes
- Enrollment goals specified to achieve inclusive trial participation reflective of the real-world demographic
- To ensure representativeness, participant demographics will be tracked for:
  - Gender
  - Race / Ethnicity
  - Age
  - Socioeconomic status

## CONCLUSIONS

- Anti-obesity medications (i.e., incretin mimetics) have the potential to curb the obesity epidemic, reduce the prevalence of obesity and overweight and improve health outcomes
- The ongoing VANQUISH-1 trial will provide further data regarding the efficacy and safety of the dual GLP-1/GIP receptor agonist VK2735 for weight loss in adults with obesity or overweight
- Measures that influence treatment adherence and persistence will also be collected (e.g., health-related quality of life, physical and mental well-being, work productivity, and treatment satisfaction)

## GLP-1 / GIP Mechanism of Action




## Key Inclusion Criteria

- Adults ≥18 years of age
- Obesity or Overweight
- BMI ≥30 kg/m<sup>2</sup> or
- BMI ≥27 kg/m<sup>2</sup> and ≥1 weight-related co-morbid condition

## Key Exclusion Criteria

- History of diabetes
- Prior or planned bariatric surgery
- Recent significant weight changes (≥5% within 3 months of screening)
- History of acute or chronic pancreatitis
- Impaired renal function
- Use of any GLP-1 RA or dual GLP-1/GIP receptor agonist or analogs within 6 months of screening

## >120 Study Sites Now Enrolling in the US



## REFERENCES

- Emmerich SD, Fryar CD, Stierman B, Ogden CL. NCHS Data Brief, no 508. National Center for Health Statistics. 2024.
- Ng M. Lancet. 2024;404(10469):2278–2298.
- NCD Risk Factor Collaboration (NCD-RisC). Lancet. 2024;403(10431):1027–1050.
- Powell-Wiley TM, Poirier P, Poirier LE, et al. Circulation. 2021;143:e984–e1010.
- Kritchevsky SB, Beavers KM, Miller ME, et al. PLoS One. 2015;10(3):e0121993.

## ACKNOWLEDGEMENTS

Neva West, PhD (NeuroWest Solutions, Chicago, IL) provided medical writing and editorial support funded by Viking Therapeutics, Inc.

## DISCLOSURES

All authors are employees of Viking Therapeutics, Inc.